Drug pipeline targeting heme biology to treat porphyrias, cancer, and tissue injury.
Velorum Therapeutics is a clinical-stage drug development company focused on unlocking the biology of heme, an iron-containing molecule essential for oxygen transport and cellular detoxification. The pipeline targets diseases caused by dysregulated heme synthesis or transport, including porphyrias (EPP and XLP), cancer growth driven by heme consumption, and organ toxicity from heme release. Velorum aims to develop transformative medicines for patients with unmet medical needs. Velorum Therapeutics is a product of Velorum Therapeutics.